|Articles|May 15, 2003
- BioPharm International-05-01-2003
- Volume 16
- Issue 5
Demonstrating the Consistency of Small Data Sets: Application of the Weisberg t-test for Outliers
by Robert J. Seely, Amgen, Inc. Louis Munyakazi, John Haury, Heather Simmerman, W. Heath Rushing, and Thomas F. Curry Determining whether a data point is an "outlier" ? a result that doesn't fit, that is too high or too low, that is extreme or discordant ? is difficult when using small data sets (such as the data from three, four, or five conformance runs). The authors show that the Weisberg t-test is a powerful tool for detecting deviations in small data sets.
Advertisement
Articles in this issue
over 22 years ago
Sumeria to Satellites: Evolution of the Bioreactorover 22 years ago
Patent Law: Extracting Maximum Value from Your Patent Portfolioover 22 years ago
Inside Washington: Medication Safety in the Limelightover 22 years ago
Part 11 Is Not Going Away: The New Electronic Records Draft Guidanceover 22 years ago
Survival Strategies: The Life Sciences Industry Turns to eLearningNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5
